TY - JOUR AU - Kato, Motoyasu AU - Shukuya, Takehito AU - Takahashi, Fumiyuki AU - Mori, Keita AU - Suina, Kentaro AU - Asao, Tetsuhiko AU - Kanemaru, Ryota AU - Honma, Yuichiro AU - Muraki, Keiko AU - Sugano, Koji AU - Shibayama, Rina AU - Koyama, Ryo AU - Shimada, Naoko AU - Takahashi, Kazuhisa PY - 2014 DA - 2014/07/10 TI - Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease JO - BMC Cancer SP - 508 VL - 14 IS - 1 AB - Non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) need to be approached carefully given the high incidence of pulmonary toxicity. Pemetrexed (PEM) is the key drug for the treatment of NSCLC. However, its safety, especially with respect to the exacerbation of ILD, and efficacy in NSCLC patients with ILD have yet to be established. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-14-508 DO - 10.1186/1471-2407-14-508 ID - Kato2014 ER -